0000000000273330

AUTHOR

Carole Vaysse

showing 2 related works from this author

Plasma omega 3 polyunsaturated fatty acids and macular pigment optical density in subjects at high risk for age-related macular degeneration: the Lim…

2016

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.; Purpose: In numerous epidemiological studies, omega 3 polyunsaturated fatty acids (PUFAs) have been associated with a decreased risk of age-related macular degeneration (AMD). Beyond their structural, functional and neuroprotective roles, omega 3 PUFAs may favor the retinal accumulation of lutein and zeaxanthin and thus increase macular pigment optical density (MPOD). We examined the associations of MPOD with plasma omega 3 PUFAs in subjects with at least one parent affected by neovascular AMD. Methods: The Limpia study is a double-blind, placebo controlled, prospective randomize…

[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologymacular degenerationgenetic structuresdmlaophtalmologiefood and beveragesvision disordersdégénérescence maculaireage differencesacide gras oméga 3eye diseasesâgeophthalmology[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyOphtalmologysense organstrouble de la vision[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory OrgansComputingMilieux_MISCELLANEOUS[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Safety and Tolerance Evaluation of Milk Fat Globule Membrane-Enriched Infant Formulas: A Randomized Controlled Multicenter Non-Inferiority Trial in H…

2014

ObjectiveThis multicenter non-inferiority study evaluated the safety of infant formulas enriched with bovine milk fat globule membrane (MFGM) fractions.MethodsHealthy, full-term infants ( n = 119) age ≤14 days were randomized to standard infant formula (control), standard formula enriched with a lipid-rich MFGM fraction (MFGM-L), or standard formula enriched with a protein-rich MFGM fraction (MFGM-P). Primary outcome was mean weight gain per day from enrollment to age 4 months (non-inferiority margin: –3.0 g/day). Secondary (length, head circumference, tolerability, morbidity, adverse events) and exploratory (phospholipids, metabolic markers, immune markers) outcomes were also evaluated.Res…

safetymedicine.medical_specialtyinfant feedingbusiness.industrygrowthGeneral Engineeringlcsh:RJ1-570lcsh:PediatricsGastroenterologyPrimary outcomeTolerabilityStandard infant formulaformula toleranceInternal medicineMedicineNon inferiority trialGlobules of fatmedicine.symptombusinessAdverse effectMilk fat globuleWeight gainBiomedical engineeringOriginal Researchmilk fat globule membraneClinical Medicine Insights: Pediatrics
researchProduct